TEL AVIV, Israel, April 25, 2018 /PRNewswire/ --
Israeli startup Kanabo Research, which
develops clinical solutions for extraction and vaporization of
medical cannabis, announces it is entering an agreement with
Constance Therapeutics, a US-based medical cannabis extraction
company.
(Photo:
https://mma.prnewswire.com/media/682136/Constance_Therapeutics_and_Kanabo_Research.jpg
)
According to the agreement, both
companies will operate in the EU to establish a cannabis
cultivation farm as well as manufacturing capabilities of cannabis
active compounds - THC and CBD - to be used in an array of medical
treatments and chronic ailments such as insomnia, PTSD and chronic
pain. Simultaneously, Constance Therapeutics will market Kanabo
Research's solutions in the US market where Constance Therapeutics
has been operating since 2008.
"We are happy to join hands with a
medical cannabis market leader like Constance Therapeutics which
will allow us to strengthen our presence in the American market,"
said Avihu Tamir, co-founder and CEO
of Kanabo Research. "At the same time, we are operating to locate
global opportunities in light of the fact that many countries are
asking to join the medical cannabis revolution. The move will allow
us to accelerate our manufacturing pace - especially important now
because of the delays in medical cannabis export approvals in
Israel - and will provide us with
an excellent base for additional operations in other markets,
primarily European markets."
Kanabo Research has seen significant
momentum in the last few months. Recently, the company received
initial approvals from Israel's
Ministry of Health to use cannabis with its proprietary VapePod
vaporizer. Similarly, the company has commenced pre-clinical trials
of Kanabo's proprietary formulations that focus on sleep disorders
and in the future for patients suffering from PTSD.
"Constance Therapeutics is excited to
partner with Kanabo Research. Kanabo is similarly focused on
research and evidence-based solutions in the cannabis space as we
are at Constance Therapeutics," said Constance Finley, Founder and CEO of Constance
Therapeutics. "The standardization Constance Therapeutics pioneered
in extracts, Kanabo matches in its precision dosing hardware.
This is a natural fit and extends each company's expertise
into new territories and most importantly, offers emerging cannabis
customers the most innovative and enjoyable option."
About Kanabo Research
Israeli Startup Kanabo Research
conducts research and development of medical cannabis extraction
and vaporization solutions. Kanabo's vaporization device - VapePod
- allows patients to inhale natural cannabis and increase
effectiveness without any smoke. Similarly, the device, which is
patent protected, lets patients monitor the dosage precisely and
over time. Kanabo's extraction pods, which are based on extensive
medical trials and in cooperation with leading doctors in
Israel and around the world,
provide treatments that target central nervous system disorders
affecting sleep, anxiety and chronic pain.
The company was founded in 2016 by CEO,
Avihu Tamir, and COO, David Sack. Among the partners and investors are
David Tsur, Co-founder and former
Chief Executive Officer of Kamada Ltd. (NASDAQ: KMDA). Dr.
Doron Friedman, CTO with over 25
years' experience as a biomedical entrepreneur and executive. Dr.
Friedman is the inventor of Bausch and
Lomb's Lotemax eye drops, and holds over 80
patents. And Dr. Nachshon Knoler,
world-renowned neurosurgeon, currently Director of the Department
of Neurosurgery at Sheba Medical Center in Tel-Hashomer,
Israel.
Kanabo Research operates in the Science
Park at Weitzman Institute. Visit:
http://www.kanaboresearch.com/
About Constance
Therapeutics
Constance Therapeutics is a
vertically-integrated medicinal cannabis company producing
standardized, science-based whole-plant cannabis extracts. These
extracts fill the gap between traditional pharmaceuticals and
commonplace cannabis products, providing much needed additional
treatment options for physicians and their patients.
Constance Therapeutics' extracts are
derived from fully trimmed, female, unfertilized cannabis flowers
of plants with known genetics using certified organic,
pharmaceutical-grade ethanol via a highly-controlled,
quantitatively defined and patented process based on solid
scientific and engineering principles. Extracts are systematically
third-party tested and routinely cross-tested in the industry's
most respected laboratories. Since 2008, the company has employed
stringent, science-based processes and standards to ensure the
highest quality and consistency.
Headquartered in San Francisco, CA, and recently permitted
under the new California
regulations, Constance Therapeutics' cannabis extracts have
historically been available exclusively for therapeutic use by
registered California patients
under Proposition 215 and California Senate Bill 420. With the new
California regulations, in
addition to continuing to serve their physician referred medical
patients, Constance Therapeutics will distribute their products
throughout the state for sale in licensed dispensaries.
Additionally, Constance Therapeutics is underway with globally
licensing their patented formulations for sale in legal markets
across the world. For further information, visit
http://www.constancetherapeutics.com.